GW Pharmaceuticals (NASDAQ: GWPH ) has agreed to sel l its Rare Pediatric Disease Priority Review Voucher that it received when Epidiolex was approved in the U.S. for rare types of epilepsy for $105M to an unnamed buyer. More news on: GW Pharmaceuticals plc, Biohaven Pharmaceutical Holdin…